Skip to content

A multicenter study on the heterogeneity of clinical and imaging features in cerebral small vessel disease and its neuromodulation.

A multicenter study on the heterogeneity of clinical and imaging features in cerebral small vessel disease and its neuromodulation.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124404
Enrollment
Unknown
Registered
2026-05-12
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral small vessel disease (CSVD)

Interventions

Primary Motor Cortex + Cerebellar Target Group:Transcranial Magnetic Stimulation
Sham TMS Group:Transcranail Magnetic Stimulation
Primary Motor Cortex Target Group:Transcranial Magnetic Stimulation
Cohort Study Group:None

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Present with at least one of the imaging diagnostic markers of CSVD according to the Chinese Guidelines for Diagnosis and Treatment of Cerebral Small Vessel Disease 2020; 2. Aged >=18 years; 3.Provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Stenosis >=50% of the cervical and/or intracranial large arteries (basilar artery, vertebral artery, anterior cerebral artery, middle cerebral artery (M1–M2 segments), and posterior cerebral artery) diagnosed by ultrasound or imaging; 2. Acute non-lacunar ischemic stroke occurring within the past 30 days, or a pre-existing cerebrovascular disease that has resulted in functional disability with a modified Rankin Scale (mRS) score >=2; 3. Intracranial hemorrhagic lesions (including cerebral hemorrhage, subarachnoid hemorrhage, epidural/subdural hemorrhage, etc.), traumatic brain injury, cerebral vascular malformation, or aneurysm occurring within the past 30 days; 4. Presence of severe systemic disease, cancer, or trauma; 5. Presence of other causes of neurological dysfunction (e.g., poisoning, alcohol abuse, drug addiction, epilepsy, encephalitis, or normal-pressure hydrocephalus); 6. Presence of other neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) or non-vascular white matter diseases (e.g., multiple sclerosis, inflammation, tumors, adult-onset leukodystrophy, metabolic encephalopathy); 7. Presence of psychiatric disorders or severe depression; 8. Severe impairment of vision, hearing, language function, or limb muscles, or inability to cooperate with examination personnel, precluding completion of relevant assessments; 9. Contraindications to MRI scanning for any reason (e.g., claustrophobia, implanted pacemaker, etc.) or poor MRI image quality; 10. Pregnancy or breastfeeding; 11. Unwillingness to receive follow-up or poor treatment adherence.

Design outcomes

Primary

MeasureTime frame
Gait Analysis;Magnetic Resonance Imaging;

Secondary

MeasureTime frame
Near-infrared Funcitonal Brain Imaging;Clinical Symptom Assessment;Eye Tracker;

Countries

China

Contacts

Public ContactBingwei Zhang

The First Affiliated Hospital of Dalian Medical University

zhangbingweidoc@163.com+86 411 83635963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026